WO2012128530A3 - 항암 활성을 가지는 2-메틸-2-알킬-6-아미도-2ｈ-벤조피란 유도체 - Google Patents

항암 활성을 가지는 2-메틸-2-알킬-6-아미도-2ｈ-벤조피란 유도체 Download PDF

Info

Publication number
WO2012128530A3
WO2012128530A3 PCT/KR2012/001971 KR2012001971W WO2012128530A3 WO 2012128530 A3 WO2012128530 A3 WO 2012128530A3 KR 2012001971 W KR2012001971 W KR 2012001971W WO 2012128530 A3 WO2012128530 A3 WO 2012128530A3
Authority
WO
WIPO (PCT)
Prior art keywords
amido
alkyl
methyl
benzopyran derivatives
cancer activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/001971
Other languages
English (en)
French (fr)
Other versions
WO2012128530A2 (ko
Inventor
공영대
김정엽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE
Industry Academic Cooperation Foundation of Dongguk University
Korea Health Industry Development Institute
Original Assignee
KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE
Industry Academic Cooperation Foundation of Dongguk University
Korea Health Industry Development Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE, Industry Academic Cooperation Foundation of Dongguk University, Korea Health Industry Development Institute filed Critical KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE
Publication of WO2012128530A2 publication Critical patent/WO2012128530A2/ko
Publication of WO2012128530A3 publication Critical patent/WO2012128530A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 우수한 NF-ĸB 표적유전자 발현 억제 활성을 가지는 신규 2-메틸-2-알킬-6-아미도-2H-벤조피란 유도체와 약제학적으로 허용 가능한 이의 염, 이 화합물의 제조방법, 그리고 이 화합물의 항암제로서의 용도에 관한 것이다.
PCT/KR2012/001971 2011-03-21 2012-03-20 항암 활성을 가지는 2-메틸-2-알킬-6-아미도-2ｈ-벤조피란 유도체 Ceased WO2012128530A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110025075A KR101071359B1 (ko) 2011-03-21 2011-03-21 항암 활성을 가지는 2-메틸-2-알킬-6-아미도-2ｈ-벤조피란 유도체
KR10-2011-0025075 2011-03-21

Publications (2)

Publication Number Publication Date
WO2012128530A2 WO2012128530A2 (ko) 2012-09-27
WO2012128530A3 true WO2012128530A3 (ko) 2012-12-27

Family

ID=45032515

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/001971 Ceased WO2012128530A2 (ko) 2011-03-21 2012-03-20 항암 활성을 가지는 2-메틸-2-알킬-6-아미도-2ｈ-벤조피란 유도체

Country Status (2)

Country Link
KR (1) KR101071359B1 (ko)
WO (1) WO2012128530A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111233809B (zh) * 2020-01-16 2021-12-03 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 一种Millepachine-CA-4衍生物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100429609B1 (ko) * 1999-10-21 2004-05-03 동부한농화학 주식회사 벤조피라닐 구아니딘 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물
KR100704009B1 (ko) * 2005-08-30 2007-04-04 한국화학연구원 염증억제 활성을 가지는6-알킬아미노-2-메틸-2'-(ｎ-메틸치환술폰아미도)메틸-2ｈ-1-벤조피란 유도체
KR20090022398A (ko) * 2007-08-30 2009-03-04 한국화학연구원 2-메틸-2'-하이드록시메틸-6-아미도벤조피란 유도체 또는 약제학적으로 허용 가능한 그의 염을 유효성분으로 함유하는 알레르기 질환 치료제
KR20090022070A (ko) * 2007-08-29 2009-03-04 한국화학연구원 2-메틸-2'-하이드록시메틸-6-아미도 벤조피란 유도체 및약제학적으로 허용 가능한 그의 염, 그의 제조방법, 그를유효성분으로 함유하는 산화스트레스 억제용 조성물 및그를 이용한 약리학적인 용도
KR20110012090A (ko) * 2009-07-29 2011-02-09 한국화학연구원 2-메틸-2ｈ-크로멘-2-카르복사미드 화합물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164509A (en) * 1990-11-26 1992-11-17 E. R. Squibb & Sons, Inc. Benzodiazolo analogs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100429609B1 (ko) * 1999-10-21 2004-05-03 동부한농화학 주식회사 벤조피라닐 구아니딘 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물
KR100704009B1 (ko) * 2005-08-30 2007-04-04 한국화학연구원 염증억제 활성을 가지는6-알킬아미노-2-메틸-2'-(ｎ-메틸치환술폰아미도)메틸-2ｈ-1-벤조피란 유도체
KR20090022070A (ko) * 2007-08-29 2009-03-04 한국화학연구원 2-메틸-2'-하이드록시메틸-6-아미도 벤조피란 유도체 및약제학적으로 허용 가능한 그의 염, 그의 제조방법, 그를유효성분으로 함유하는 산화스트레스 억제용 조성물 및그를 이용한 약리학적인 용도
KR20090022398A (ko) * 2007-08-30 2009-03-04 한국화학연구원 2-메틸-2'-하이드록시메틸-6-아미도벤조피란 유도체 또는 약제학적으로 허용 가능한 그의 염을 유효성분으로 함유하는 알레르기 질환 치료제
KR20110012090A (ko) * 2009-07-29 2011-02-09 한국화학연구원 2-메틸-2ｈ-크로멘-2-카르복사미드 화합물

Also Published As

Publication number Publication date
KR101071359B1 (ko) 2011-10-07
WO2012128530A2 (ko) 2012-09-27

Similar Documents

Publication Publication Date Title
MY165087A (en) Neprilysin inhibitors
EP2668184A1 (en) Derivatives of azaindazole or diazaindazole type as medicament
WO2011012816A3 (fr) Formulation pharmaceutique
ZA201404273B (en) 2',4'-diflouro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
HK1210782A1 (en) Lfa-1 inhibitor and polymorph thereof
HK1210775A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
HK1198442A1 (en) Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
CA2873723A1 (en) Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
WO2012065019A3 (en) Combination comprising pyridopyrimidinone inhibitors of pi3k alpha
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
WO2013093931A3 (en) Novel prodrugs of phenolic drugs
CL2014000998A1 (es) Compuestos heterociclicos derivados de azepan-4-ona, inhibidores de la actividad desubiquitinante; composicion farmaceutica; uso para tratar cancer resistente a la quimioterapia.
WO2013128379A3 (en) Crystalline polymorphic forms of linagliptin
WO2014062838A3 (en) Pkm2 modulators and methods for their use
WO2012150606A3 (en) A process for preparing stable polymophic form of erlotinib hydrochloride
MX2014015345A (es) Inhibidores piranopiridona de tanquirasa.
WO2011123524A3 (en) Macrolide inhibitors of mtor
HK1205095A1 (en) Methods and intermediates for preparing pharmaceutical agents
PL2865664T3 (pl) Nowy związek mający zdolność hamowania enzymu 11ß-HSD1, lub jego farmaceutycznie dopuszczalna sól, sposób wytwarzania go, i kompozycja farmaceutyczna zawierająca go jako składnik aktywny
WO2012018791A3 (en) Preparation of prasugrel hydrochloride
WO2012154879A3 (en) Autophagy inhibitors
AU2012225365A8 (en) Peptide deformylase inhibitors
WO2013062332A3 (ko) 시링가레시놀을 포함하는 혈관 노화 억제용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12760539

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12760539

Country of ref document: EP

Kind code of ref document: A2